Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Thromb Thrombolysis

Search In Journal Title:

Abbravation: Journal of Thrombosis and Thrombolysis

Search In Journal Abbravation:

Publisher

Kluwer Academic Publishers-Plenum Publishers

Search In Publisher:

DOI

10.1007/978-1-84882-262-7_15

Search In DOI:

ISSN

1573-742X

Search In ISSN:
Search In Title Of Papers:

In vitro shear stress modulates antithrombogenic p

Authors: Zhen Yang Jiemei Wang Lichun Wang Long Chen Chang Tu Chufang Luo Anli Tang ShengMing Wang Jun Tao
Publish Date: 2007/01/13
Volume: 23, Issue: 2, Pages: 121-127
PDF Link

Abstract

Recent study suggested that endothelial progenitor cells EPCs a novel therapeutic approach for endothelial dysfunction present limited antithrombogenic potentials However few attempts have been done to improve the antithrombogenic potentials of EPCs Our previous study proved that in vitro shear stress contributes to the increase in tPA production by human EPCs Here we further investigated whether in vitro shear stress contributes to the secretion of antithrombogenic substances including plasminogen activator inhibitor1 PAI1 and prostaglandin I2 PGI2 by human EPCsThe peripheral blood mononuclear cells of healthy subjects were induced into EPCs Then the human EPCs were treated with four levels of shear stress including stationary condition low media and high flow shear stress The production of PAI1 and 6ketoprostaglandin F11α6KetoPGF1α by human EPCs with shear stress treatment were measuredIn vitro medium and high flow shear stress inhibited PAI1 secretion by human EPCs but low flow shear stress had no effect on PAI1 secretion by human EPCs All levels of shear stress significantly increased 6KetoPGF1α production by human EPCs in a dosedependent manner


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. The inhibition in tumor necrosis factor-α-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-κB and reactive oxygen species
  2. Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction
  3. Does supervised exercise after deep venous thrombosis improve recanalization of occluded vein segments? A randomized study
  4. Anticoagulation in the management of venous thromboembolism in the cancer patient
  5. Association between sleep condition and arterial stiffness in Chinese adult with nonalcoholic fatty liver disease
  6. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease
  7. Role of thrombophilia testing: con
  8. Venous thromboembolism and cancer: a systematic review
  9. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG ® ) to guide decision-making
  10. Proceedings of the 10th National Conference on Anticoagulant Therapy
  11. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device
  12. The relationship between gender and age with monocyte tissue factor expression
  13. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
  14. A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience
  15. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
  16. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
  17. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine
  18. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention
  19. Cardiovascular risk factors and outcome in patients with retinal vein occlusion
  20. Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East
  21. Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study
  22. Increased platelet activation in patients with slow coronary flow
  23. Biomarkers of deep venous thrombosis
  24. Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study
  25. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
  26. New oral Xa and IIa inhibitors: updates on clinical trial results
  27. Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study
  28. Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra ( Naja naja ) venom
  29. Evaluation of the Alere D-dimer test for point of care testing
  30. Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves
  31. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial
  32. Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
  33. Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis
  34. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?
  35. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait

Search Result: